Editas Medicine AI Stock Analysis
Editas Medicine (8EM) AI Stock Analysis
Editas Medicine
(BX Swiss:8EM)
No summary available
Editas Medicine (8EM) vs. iShares MSCI Switzerland ETF (EWL)
- Market Cap
- CHF 365.52M
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -3.9
- Beta (1Y)
- 0.83
- Revenue Growth
- -0.56%
- EPS Growth
- 76.09%
- Country
- Switzerland
- Employees
- 87
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Editas Medicine Business Overview & Revenue Model
Company Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead...
Editas Medicine Earnings Call Summary
The call highlighted significant progress in both clinical trials and in vivo pipeline development. Financial stability was assured despite a higher burn rate. However, challenges such as increased expenses and regulatory issues around fertility support present hurdles. Overall, the company's advancements in gene editing and robust clinical trial outcomes provide a positive outlook.
Q2-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During the Editas Medicine Q2 2024 earnings call, CEO Gilmore O'Neill outlined the company's strategic progress, emphasizing three main pillars: advancing reni-cel towards BLA and commercialization, building a differentiated in vivo editing pipeline, and enhancing business development with a focus on intellectual property. The RUBY trial data for sickle cell disease showed promising results, with 18 patients having follow-up periods ranging from 2.4 to 22.8 months and demonstrating robust anemia correction. The EdiTHAL trial for beta-thalassemia included data from 7 patients with 4.1 to 12.8 months follow-up. Financially, Editas reported cash, cash equivalents, and marketable securities totaling $318 million as of June 30, 2024, with a burn rate increase due to R&D expenses. They expect to fund operations into 2026. The company is also on track to establish in vivo preclinical proof of concept by year-end, with a focus on leveraging indel technology for gene upregulation, targeting rare and orphan diseases initially.
Editas Medicine Risk Analysis
Editas Medicine disclosed 73 risk factors in its most recent earnings report. Editas Medicine reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksEditas Medicine Peers Comparison
Overall Rating
VOR50Neutral
CLLS44Neutral
FHTX41Neutral
ELTX39Underperform
CRBU38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| VOR | 50Neutral | $1.20B | 0.07 | -830.38% | ― | ― | ― |
| CLLS | 44Neutral | $84.19M | -2.29 | -94.14% | ― | -0.11% | -13.99% |
| FHTX | 41Neutral | $113.93M | 29.86 | -14.17% | ― | 357.33% | ― |
| ELTX | 39Underperform | $45.57M | -0.89 | -529.69% | ― | ― | 46.62% |
| CRBU | 38Underperform | $44.34M | -0.38 | -102.74% | ― | 1.60% | 39.34% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CH:8EM | Editas Medicine Inc. | 2.05 | -0.87 | -29.67% | |
| CLLS | Cellectis S.A. | 1.38 | -2.19 | -61.34% | |
| FHTX | Foghorn Therapeutics, Inc. | 2.09 | -2.27 | -52.06% | |
| ELTX | Elicio Therapeutics, Inc | 1.63 | -7.48 | -82.11% | |
| VOR | Vor Biopharma, Inc. | 20.09 | 10.34 | 106.05% | |
| CRBU | Caribou Biosciences, Inc. | 0.39 | -1.59 | -80.30% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.